Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
C. Cheng
Institution:
Eli Lilly (United States)
Observed institution:
Eli Lilly (United States)
OpenAlex ID:
A5114034356
The effects of LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, in a randomized, placebo‐controlled, double‐blind study of overweight/obese patients with type 2 diabetes: the EGO study
2011
·
G. E. Umpierrez
, T. Blevins
, et al.
·
Diabetes Obesity and Metabolism
·
87
KGF induces TGFα expression and activates the EGF receptor signaling pathway to alter keratinocyte growth and differentiation in vitro
1993
·
A.A. Dlugosz
, C. Cheng
, et al.
·
Journal of Dermatological Science
·
2
Effect of LY2189265, a long-acting glucagon-like peptide 1 analog, on metabolic outcomes and GI events in obese patients with uncontrolled type 2 diabetes mellitus (T2DM): The EGo study.
2009
·
G. Umpierrez
, T. Blevins
, et al.
·
Canadian Journal of Diabetes
·
1
Involvement of cholinergic receptor in dorsal facial area for regulation of common carotid arterial blood flow in cats
2004
·
龔志力
, Y. T. Chiu
, et al.
Show more works
View as search
Works count:
4
Citation count:
90
H-index:
2
I10-index:
1
Year
Topic
Type